HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California’s Fragrance ‘Right To Know’ Act Kicks In With Important Questions Unresolved

Executive Summary

California legislation is now in effect requiring cosmetics companies to begin reporting to the state’s public health department use of fragrance and flavor ingredients that appear on any of 23 authoritative lists. Industry says compliance efforts are underway, but important questions remain, including about disclosure of essential oil components and other naturally occurring chemicals.

You may also be interested in...



Cosmetics Industry Awaits FDA’s Allergen List While Working To Inform GMP Rulemaking

The Independent Beauty Association does not yet have insight into what ingredients will be listed in the US FDA’s proposed rulemaking for cosmetic allergen labeling – due by 29 June – but is optimistic the agency will consult industry when it comes to setting the compliance timeline. Meanwhile, industry stakeholders are pushing for international harmonization in the agency’s cosmetic GMPs rulemaking.

When It Rains: Global Fragrance Giants Under Investigation For Collusion Face US Class Actions

Class action complaints in New Jersey federal court against Firmenich, Givaudan, IFF, and Symrise follow an investigation announced in March into potential violations of cartel law and raids orchestrated by the European Commission, US Department of Justice, UK Competition and Markets Authority, and others.

US Cosmetics Companies Doing Gap Analysis, Awaiting FDA Instruction In MoCRA’s First Year

Amin Talati Wasserman attorney Angela Diesch discusses the priorities, questions and concerns among companies facing end-of-year deadlines under the Modernization of Cosmetic Regulations Act enacted in the final days of 2022.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel